Goldman Sachs Group Inc. bought a new stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 11,569 shares of the biotechnology company’s stock, valued at approximately $277,000. Goldman Sachs Group Inc. owned approximately 0.06% of AnaptysBio at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of AnaptysBio by 22.6% during the 2nd quarter. Vanguard Group Inc. now owns 206,031 shares of the biotechnology company’s stock valued at $4,931,000 after purchasing an additional 37,932 shares in the last quarter. Northern Trust Corp boosted its stake in shares of AnaptysBio by 360.6% during the 2nd quarter. Northern Trust Corp now owns 60,042 shares of the biotechnology company’s stock valued at $1,436,000 after purchasing an additional 47,005 shares in the last quarter. Artal Group S.A. boosted its stake in shares of AnaptysBio by 459.4% during the 2nd quarter. Artal Group S.A. now owns 250,000 shares of the biotechnology company’s stock valued at $5,983,000 after purchasing an additional 205,310 shares in the last quarter. New York State Common Retirement Fund bought a new stake in shares of AnaptysBio during the 2nd quarter valued at about $168,000. Finally, TIAA CREF Investment Management LLC boosted its stake in shares of AnaptysBio by 69.2% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 13,844 shares of the biotechnology company’s stock valued at $331,000 after purchasing an additional 5,663 shares in the last quarter. 59.04% of the stock is currently owned by hedge funds and other institutional investors.

In related news, major shareholder Holdings A/S Novo sold 356,300 shares of AnaptysBio stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $21.10, for a total transaction of $7,517,930.00. Following the completion of the transaction, the insider now directly owns 1,936,604 shares of the company’s stock, valued at approximately $40,862,344.40. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

COPYRIGHT VIOLATION WARNING: “Goldman Sachs Group Inc. Buys New Position in AnaptysBio, Inc. (ANAB)” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.thecerbatgem.com/2017/11/19/goldman-sachs-group-inc-buys-new-position-in-anaptysbio-inc-anab.html.

A number of brokerages have recently weighed in on ANAB. SunTrust Banks, Inc. began coverage on shares of AnaptysBio in a research note on Wednesday. They set a “buy” rating and a $115.00 target price on the stock. Royal Bank Of Canada lifted their target price on shares of AnaptysBio from $40.00 to $79.00 and gave the company an “outperform” rating in a research note on Tuesday, October 10th. Credit Suisse Group lifted their target price on shares of AnaptysBio from $38.00 to $85.00 and gave the company an “outperform” rating in a research note on Tuesday, October 10th. Robert W. Baird set a $69.00 target price on shares of AnaptysBio and gave the company a “buy” rating in a research note on Wednesday, October 11th. Finally, Zacks Investment Research cut shares of AnaptysBio from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $84.78.

AnaptysBio, Inc. (NASDAQ ANAB) opened at $76.64 on Friday. AnaptysBio, Inc. has a 12-month low of $15.17 and a 12-month high of $79.18. The company has a quick ratio of 10.77, a current ratio of 10.77 and a debt-to-equity ratio of 0.09.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.02. equities analysts forecast that AnaptysBio, Inc. will post -1.72 earnings per share for the current fiscal year.

AnaptysBio Company Profile

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Institutional Ownership by Quarter for AnaptysBio (NASDAQ:ANAB)

Receive News & Stock Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related stocks with our FREE daily email newsletter.